申请人:RAPPTA THERAPEUTICS OY
公开号:WO2021170913A1
公开(公告)日:2021-09-02
Chemical modulators of PP2A, comprising tricyclic sulfonimidamides are disclosed. The compounds are useful in preventing or treating cancer, diabetes, autoimmune disease, solid organ transplant rejection, graft vs host disease, chronic obstructive pulmonary disease (COPD), non-alcoholic fatty liver disease, abdominal aortic aneurysm, chronic liver disease, heart failure, neurodegenerative disease and cardiac hypertrophy. The compounds are of formula (I)
化学调节剂PP2A,包括三环磺胺亚胺类化合物。这些化合物对预防或治疗癌症、糖尿病、自身免疫疾病、固体器官移植排斥、移植物抗宿主病、慢性阻塞性肺疾病(COPD)、非酒精性脂肪肝病、腹主动脉瘤、慢性肝病、心力衰竭、神经退行性疾病和心肌肥大具有用处。这些化合物的化学式为(I)。